The abstract is read at the publisher; the summary is JClub's.
Davunetide shows a significant treatment effect favoring women on the FDA-recommended 10-item PSP Rating Scale (PSPRS-10) over 52 weeks in progressive supranuclear palsy, with P = 0.0005.
- Why it matters: PSP is a fatal tauopathy with unmet need, and prior sex-split PSP trials suggested women might benefit, but the FDA-recommended PSPRS-10 had not been evaluated longitudinally.
- What they did: Using 52-week longitudinal data, the study applied FDA-recommended PSPRS-10 and PSPRS-28 with linear mixed-effects models (MMRM), plus RBANS cognitive testing and CSF p-Tau/Tau correlations with functional outcomes.
- The result: Women improved on RBANS total raw score, letter-number sequencing, and language, and CSF p-Tau/Tau ratio correlated with involuntary-action behavior in opposite directions by sex (females r = 0.77, P = 0.006; males r = -0.62, P = 0.075; sex difference P = 0.0002).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.